IDEAS home Printed from https://ideas.repec.org/a/vra/journl/v9y2020i3p52-62.html
   My bibliography  Save this article

Orphan Drugs of Personalized Medicine in Bulgaria and Their Cost-Effectiveness

Author

Listed:
  • Zhaklin Stoykova-Valcheva

    (Medical University-Varna - Varna, Varna, Bulgaria)

Abstract

The orphan drugs development is related to the progress of personalized medicine. The relationship between them is based on a treatment tailored to personalized patient needs. Personalized medicine is defined as “providing the right patient with the right drug, at the right dose and at the right time”, while the orphan drug is defined as “intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the United States” and no more than 10,000 people for the European Union. The main goal of the article is to study the approved orphan drugs in Bulgaria, determining how many of them are reimbursed by the NHIF and are cost-effective.

Suggested Citation

  • Zhaklin Stoykova-Valcheva, 2020. "Orphan Drugs of Personalized Medicine in Bulgaria and Their Cost-Effectiveness," Izvestia Journal of the Union of Scientists - Varna. Economic Sciences Series, Union of Scientists - Varna, Economic Sciences Section, vol. 9(3), pages 52-62, December.
    • Handle: RePEc:vra:journl:v:9:y:2020:i:3:p:52-62
    DOI: 10.36997/IJUSV-ESS/2020.9.3.52
    as

    Download full text from publisher

    File URL: http://su-varna.org/journal/IJUSV-ESS/2020.9.3/52-62.pdf
    Download Restriction: no
    File URL: https://libkey.io/10.36997/IJUSV-ESS/2020.9.3.52?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Ash Bullement & Paul Nathan & Anna Willis & Amerah Amin & Cameron Lilley & Ceilidh Stapelkamp & Anthony Hatswell & Chris Pescott & Murtuza Bharmal, 2019. "Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma," PharmacoEconomics - Open, Springer, vol. 3(3), pages 377-390, September.
    2. Thomas E. Delea & Xinke Zhang & Jordan Amdahl & Diana Boyko & Franziska Dirnberger & Marco Campioni & Ze Cong, 2019. "Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States," PharmacoEconomics, Springer, vol. 37(9), pages 1177-1193, September.
    3. Josh J. Carlson & Kangho Suh & Panos Orfanos & William Wong, 2018. "Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 36(4), pages 495-504, April.
    4. Eytan Stein & Jipan Xie & Emilie Duchesneau & Subrata Bhattacharyya & Umakanth Vudumula & Briana Ndife & Gaetano Bonifacio & Annie Guerin & Nanxin Li & George Joseph, 2019. "Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States," PharmacoEconomics, Springer, vol. 37(2), pages 239-253, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Keywords

      Orphan drug; Personalized medicine; Cost-effectiveness;
      All these keywords.

      JEL classification:

      • A00 - General Economics and Teaching - - General - - - General

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:vra:journl:v:9:y:2020:i:3:p:52-62. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Pavel Petrov (email available below). General contact details of provider: https://edirc.repec.org/data/uevecea.html .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.